Oruka Therapeutics (ORKA) Other Accumulated Expenses (2010 - 2024)

Oruka Therapeutics' Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $591000.0 for Q2 2024.

• On a quarterly basis, Other Accumulated Expenses fell 49.53% year-over-year to $591000.0 in Q2 2024; TTM through Jun 2024 was $591000.0, a 49.53% decrease from a year earlier, with the FY2023 full-year figure at $175000.0, down 72.0% from the prior year.
• Other Accumulated Expenses retreated to $591000.0 in Q2 2024 per ORKA's latest filing, from $968000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.9 million in Q3 2021 and bottomed at $175000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $939500.0 (2020), against an average of $959277.8.
• Across the five-year window, Other Accumulated Expenses surged 249.54% in 2021 and sank 72.0% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $911000.0 in 2020, then soared by 59.82% to $1.5 million in 2021, then slumped by 57.07% to $625000.0 in 2022, then sank by 72.0% to $175000.0 in 2023, then soared by 237.71% to $591000.0 in 2024.
• Per Business Quant, the three latest ORKA Other Accumulated Expenses figures stand at $591000.0 (Q2 2024), $968000.0 (Q1 2024), and $175000.0 (Q4 2023).